Pilot study of neoadjuvant camrelizumab plus chemotherapy for resectable esophageal squamous cell carcinoma

Programmed cell death 1 (PD-1) blockade induces tumor regression in patients with advanced esophageal squamous cell carcinoma (ESCC). Little is know about the efficacy of PD-1 blockade as neoadjuvant therapy for resectable ESCC. A pilot study at Sun Yat-sen University (Guangzhou, China) found that the combination of neoadjuvant camrelizumab with carboplatin and nab-paclitaxel for stage II/III ESCC had manageable treatment-related adverse effects and induced an objective response in 90.5% of patients.